Emerging immunotherapies in older adults with acute myeloid leukemia
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging immunotherapies in older adults with acute myeloid leukemia
Authors
Keywords
-
Journal
CURRENT OPINION IN HEMATOLOGY
Volume 20, Issue 2, Pages 107-114
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2013-01-17
DOI
10.1097/moh.0b013e32835d8101
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
- (2012) W. Blum et al. BLOOD
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia
- (2012) J. Greiner et al. BLOOD
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia
- (2012) John S. Welch et al. CELL
- Survival for older patients with acute myeloid leukemia: a population-based study
- (2012) B. Oran et al. HAEMATOLOGICA
- Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
- (2012) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
- (2012) Li Ding et al. NATURE
- HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1
- (2012) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
- (2011) Sherif S. Farag et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC
- (2011) Patrice Chevallier et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
- (2011) S. Schwind et al. BLOOD
- Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT
- (2011) S. Sivori et al. BLOOD
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
- (2011) K. H. Metzeler et al. BLOOD
- Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
- (2011) Mohamed L. Sorror et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
- (2011) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
- (2011) K H Metzeler et al. LEUKEMIA
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced Age
- (2010) John Koreth et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
- (2010) H. Becker et al. BLOOD
- Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
- (2010) P. G. Maslak et al. BLOOD
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
- (2010) S. Cooley et al. BLOOD
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects
- (2010) J. A. Olson et al. BLOOD
- IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2010) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- NK Cell Regulation of CD4 T Cell-Mediated Graft-versus-Host Disease
- (2010) M. N. Rivas et al. JOURNAL OF IMMUNOLOGY
- “Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone Marrow
- (2010) Sebastian Ochsenreither et al. JOURNAL OF IMMUNOTHERAPY
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
- (2009) Heiko Becker et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity
- (2008) D. Pende et al. BLOOD
- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
- (2008) S. Cooley et al. BLOOD
- Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias
- (2008) Alessandro Moretta et al. IMMUNOLOGICAL REVIEWS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started